Loading clinical trials...
Loading clinical trials...
Effects of Gamma-linolenic Acid Supplementation on Weight Loss Maintenance in the Virta Treatment
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight loss maintenance in Virta Health patients.
The primary purpose of this research is to determine if GLA supplementation reduces weight regain over 24 months in Virta Health patients. The secondary purpose is to determine the effect of GLA supplementation on diabetes-related outcomes.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Virta Health
San Francisco, California, United States
Start Date
July 22, 2020
Primary Completion Date
February 13, 2023
Completion Date
September 15, 2023
Last Updated
April 24, 2024
302
ACTUAL participants
gamma-linolenic acid
DIETARY_SUPPLEMENT
placebo
DIETARY_SUPPLEMENT
Lead Sponsor
Virta Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions